Global drug makers face pricing pressure as China targets affordable healthcare

China's ambitious healthcare reform initiative is intensifying competitive dynamics in the pharmaceutical sector, compelling global drug manufacturers to recalibrate their business strategies. Regulatory bodies are implementing stringent price negotiations and cost containment measures to ensure medication accessibility for citizens. This regulatory landscape presents significant challenges to profit margins, requiring pharmaceutical companies to optimize operational efficiency and explore alternative revenue models while maintaining innovation standards.